• e-Therapeutics plc, of Oxford, UK, said it started a second Phase I trial testing cancer drug ETS2101, a drug designed to promote apoptosis. The dose-escalating study is expected to enroll up to 45 patients with a variety of solid tumors.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter